Physician-scientist making medicines with friends, memories with family. EVP R&D at Amgen
Joined September 2011
- Tweets 2,601
- Following 913
- Followers 23,419
- Likes 5,220
421 Photos and videos
May 18
All in the Simi Valley area and neighboring communities, please take note of this new Sandy Fire and wind patterns. Stay safe and take best care.
#BREAKING:
Fire crews are currently battling a brush fire in Simi Valley. @LAflyingcameras overhead NOW.
Tune in to KTLA 5 or stream via the KTLA app 📲, KTLA 💻 or KTLA.com
4
4,437
May 14
ICYMI. Singer and guitarist @ericchurch at UNC Commencement. Reflective, touching, deeply affecting. Will be watching this again with Jennifer and the kids.
1
1
17
3,207
May 7
Parked right next to it at the Waxahatchee & MJ Lenderman show last evening in LA. IYKYK, respect the total commitment. Incredible performance by @MarkJLenderman @k_crutchfield @waxa_katie
5
1,373
Mar 29
Very nice study by @wgibson, on bifunctionals in gene control. The EWS-FLI1 signature impact of the JQ1-based recruiter is nice. Worth studying the AR-binding JQ1 ligands from Halda/JNJ, in this way. Contribution of RIPTAC and TCIP components would be very interesting. (Also curious if the potent aTAG-2 acetylates EWS-FLI1 or the chimeric FKBP12). Great read, Will!
Mar 28
What if a small molecule could activate a transcription factor program in one cell type and destroy the same pathway in another? In our new preprint, we describe one such story on bifunctional molecules that toggle between transactivation and repression.
1
3
64
12,042
Jay Bradner, M.D. retweeted
Mar 28
What if a small molecule could activate a transcription factor program in one cell type and destroy the same pathway in another? In our new preprint, we describe one such story on bifunctional molecules that toggle between transactivation and repression.
7
87
463
60,240
Mar 28
Telomeres are longer on the West Coast. Been in SoCal for only eight months and can already feel it. Nice GWAS on leukocyte telomere length and genetic associations in @NatureGenet by @pnatarajanmd and colleagues. nature.com/articles/s41588-0…
2
18
110
13,983
Mar 8
Learned today of the passing of Phil Low, a drug hunter, scholar, educator and just lovely man. His work to target cancer cells via folic acid receptors, among so many other creative ideas, were a source of inspiration so many years ago. It was an honor to work with him on PSMA radioligand therapy, and to develop his inventions further to real medicines while at Novartis. Phil was a dynamo in his Purdue laboratory, surrounded by adoring trainees, at a whiteboard or pounding through 80 packed Powerpoint slides in 30 breathless minutes. I am glad and better to have known you, Phil. Your memory is a blessing. linkedin.com/posts/purdue-un…
2
6
45
8,377
Feb 14
Mitochondria and Chloroplasts set aside their differences (cellular respiration vs photosynthesis, oxygen vs light, christae vs thylakoids) @GordonConf this July. @VamsiMootha accepting abstracts and terminal electrons now.
Feb 12
If you love the organelles that power life, come to @GordonConf Mito & Chloroplasts July 19-24, Maine. Please RT.
This conference (rich tradition!) will span the evolution, metabolism, and synthetic biology of these organelles.
Many oral/poster slots:
tinyurl.com/5n6upfxr
2
2
9
3,589
Jan 12
Had the pleasure of joining fellow biotech leaders at the #LongwoodHealthcareLeaders #SanFranciscoCEO meeting for a candid discussion on where R&D is headed — and how our industry must continue to evolve to meet unmet patient needs and deliver meaningful innovation.
Thank you to @LongwoodLeaders and @LongwoodFund for convening such a thoughtful group and for the opportunity to share how @Amgen is designing the medicines of tomorrow.
4
1
32
4,377
Jan 6
Thanks Bruce @LifeSciVC. Time cannot move fast enough to bring this brave idea and prototype medicine to patients with AML. As a stem cell transplant physician, I am well calibrated to the challenge AML patients face. All learnings, insights and leaders at @Amgen in ALL will be accessible to this amazing team of innovators.
Jan 6
Great to see early stage deal-making in important high need areas like AML, securing preclinical assets on novel/emerging targets. Kudos to $AMGN and @jaybradner...
For Dark Blue, having raised only ~$10M of investor capital, at at post-money of ~$20M (according to Pitchbook), this is likely a handsome return upfront and puts the asset in the hands of a smart developer.
Having M&A alternatives for preclinical assets helps drive competitive investor demand across the board, creating healthy optionality (vs a dilution-heavy, IPO-only strategy).
1
1
57
12,156
15 Dec 2025
Stunning use of dTAG to study rapid dynamics of chromatin structure and cis-regulatory interactions at high resolution. Blueprint for studying mechanistic effects of TF degraders / modulators.
14 Dec 2025
In the latest issue! Mapping chromatin structure at base-pair resolution unveils a unified model of cis-regulatory element interactions dlvr.it/TPpqpW
3
31
14,549
16 Oct 2025
An inspired choice to lead a brilliant faculty of scholars. Congratulations, @mskcc CSO Ross Levine. I knew him when, and knew it then.
Dr. Ross Levine (@rosslevinemd), Senior Vice President of Translational Research at MSK, has been named MSK's new Chief Scientific Officer (CSO).
Dr. Levine will be responsible for setting and leading strategy for basic and translational research, including programs, centers, and technology cores.
Congratulations, Dr. Levine!
bit.ly/4nQAeNj
3
97
15,665
16 Oct 2025
How to Succeed in Biotech. Part 2 of this thoughtful and insight-rich reflection by Bruce Booth @LifeSciVC, on the eve of his 20th Altas-versary. Plain spoken and approachable, a high yielding reaction. Great read whether working at a small biotech or the largest independent biotech in the world.
15 Oct 2025
Twenty Years In Early Stage Biotech VC (Part 2): People
Continuing in the trifecta of anniversary blogs, here are a few observations on people, talent and teams:
· The power of luck!
· Life is short… live by the NAR (No Asshole Rule)
· By the time you know you need a leadership change, you’re probably late
· Surround yourself with data-driven truth-seekers
· The best CEOs understand and are aligned with their current shareholders
· Most CEOs are either openers or closers, rarely both
· Build lean organizations by encouraging teams to “earn the right” to grow
· Fractional leadership in a startup works until it doesn’t.
· Leadership coaches/advisors are valuable for all types of performers
· Build authentic multi-faceted relationships with people in your biotech community
lifescivc.com/2025/10/twenty…
5
66
24,231
27 Aug 2025
Honored to keynote at Nucleate Summit 2025 with 500 brilliant entrepreneurs & scientists. The energy was electric—proof the future of biotech is in very good hands.
#MyCompany
3
1
32
3,093
18 Aug 2025
From decoding the genome’s “dark matter” to designing next-gen medicines, @HowardYChang is the ideal leader for @Amgen Research.
Tackling the toughest problems in therapeutic science requires deep insights into human biology, creative new technologies in molecular biology, comfort in computation, and a wiring for collaboration. Can think of nobody better to lead therapeutics discovery. Let's gooooo! #MyCompany
Read more: nature.com/articles/d41573-0…
3
3
62
5,007
2 Jun 2025
Big news today: Phase 3 trial results published in @NEJM highlight @Amgen innovation in small cell lung cancer (#SCLC).
🔗Read how #MyCompany is reshaping treatment options: bit.ly/3FsZ0SV
2
2
29
1,950